Goodbye Plavix, hello competition

Share this article:
Plavix ceded 90% of its market share to generics within two months
Plavix ceded 90% of its market share to generics within two months

Longtime mega-blockbuster Plavix (clopidogrel bisulfate) has gone to the branded drug beyond. The Bristol-Myers Squibb brand, far and away the No. 1 anti-platelet drug in the US from 2007 through 2011 and briefly the successor to Lipitor as biggest of all blockbusters, lost patent exclusivity Thursday.

Plavix raked in $27.2 billion in US sales alone over the past five years, so you might expect wailing and rending of garments from investors, but analysts aren't sweating it. Bernstein's Tim Anderson said in a March report that the impact will be mitigated, in part, by new drugs. “BMS is, far and away, the company that will have the biggest revenue contribution from new pipeline drugs through 2016,” said Anderson.

 

Business intelligence firm The Zitter Group's Managed Care Message Monitor shows “more messages for [AstraZeneca's Brilinta] than for any other product currently approved for acute coronary syndrome (64% of messages captured in the anticoagulant category), with a clear claim of superiority over Plavix,” in patients with acute coronary syndrome, along with quicker onset of action, they wrote. “Further competitive messaging is focused on Effient as a direct competitor, stressing the fact that Brilinta has a more favorable safety profile, while highlighting bleeding risks seen with Daiichi Sankyo's product.” Lilly and Daiichi Sankyo's "Effient messaging also claims superior efficacy and safety to Plavix, with particular emphasis on the former product's effectiveness following stent insertion surgery,” said Zitter. “Both AstraZeneca and Daiichi Sankyo are touting their superiority to Plavix, but Brilinta messaging is also competitive towards Effient.”

Johnson & Johnson's Xarelto (rivaroxaban) is not officially a Plavix competitor—the FDA hasn't cleared it for the same indication, although it's currently awaiting approval for use in reducing the risk of new heart attacks and stroke, as well as clots, in patients with acute coronary syndrome. Zitter says J&J's roundabout approach talks up how Xarelto compares to warfarin for atrial fibrillation and stroke prevention, while stressing its more convenient dosing compared to Boehringer Ingelheim's Pradaxa. Boehringer is trumpeting Pradaxa's superiority in efficacy over Xarelto.

Note: The initial version of this post incorrectly said Zitter's MCMM data has been logged since 2001. In fact, it covers only the past six months. We also wrongly said 46% of Brilinta's messaging compared the AZ product to Plavix—rather, 64% of messages captured in the anticoagulant category concerned Brilinta.
Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...